MAP2K7 and lung carcinoma: An analysis of gene expression signatures reflecting RAS pathway activation in lung cancer shows that MEK inhibitory drugs have the strongest selective effectiveness towards RAS pathway active lung cancer cell lines out of a panel of some 500 oncology drugs [29].